PREMIA Holdings

PREMIA Holdings is a precision oncology company operating in Asia through the PREMIA/Precision Medicine Asia brand. The company provides an integrated clinical-genomic development platform that helps biopharma and diagnostics companies identify biomarker-defined cancer patients, support clinical trial enrollment, generate real-world and genomic datasets, and commercialize companion diagnostics in Asia. PREMIA manages Japan-linked clinical-genomic screening infrastructure associated with LC-SCRUM and describes itself as one of the largest Asian cancer clinical-genomic screening networks. Its activities appear centered on oncology data and trial-enablement services rather than proprietary therapeutics, with notable collaborations involving AmoyDx, Loxo Oncology/Eli Lilly, and other precision oncology stakeholders. PREMIA has also participated in the Japanese commercialization of the AmoyDx Pan Lung Cancer PCR Panel for multiple targeted lung cancer therapies.